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ISSBackground: Surveillance in the era of antiretroviral therapy (ART) requires estimates of
HIV prevalence as well as the proportion eligible for ART. We estimated HIV preva-
lence and assessed field staging of individuals to estimate the burden of HIV disease
needing treatment in rural Malawi.
Methods: Adults aged 18–59 years in a demographic surveillance system were inter-
viewed, examined, and HIV counselled and tested. Staging that used a simplified
version of the WHO criteria (‘field checklist’) was compared with staging by a medical
assistant using a ‘clinic checklist’ and to CD4 cell results.
Results: A total of 2129 of 2303 eligible adults (92.4%) were traced, and 2047 (96.1%)
participated. Of the 1443 participants (70.5%) tested, 11.6% were HIV positive. ART
eligibility classification by the field and clinic checklists were concordant in 122 of 133
HIV-positive individuals. Compared with the clinic checklist, the field checklist had a
sensitivity of 50% and a specificity of 96%. Including those already known to be on
ART, staging by the field and clinic checklists estimated ART eligibility at 16.3 and
17.7% of HIV-positive individuals, respectively. Using CD4 cell count under 250 cells/
ml or WHO stage III/IV, the Malawi national programme criteria, 38% of HIV-positive
individuals were eligible for ART, compared with 31% based on the 2006 WHO criteria
of CD4 cell count under 200 cells/ml or WHO stage IV or CD4 cell count of 200–
350 cells/ml and WHO stage III.
Conclusion: The field checklist was not a suitable tool for individual staging. Criteria for
ART eligibility based on clinical staging alone missed two-thirds of those eligible by
clinical staging and CD4 cell count.
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Whereas antiretroviral therapy (ART) rollout pro-
grammes throughout sub-Saharan Africa have sought
to meet the challenge of monitoring the number of
individuals receiving treatment, none have tried directly
to measure the number of HIV-infected individuals who
meet treatment criteria in the community. Instead,
treatment need has generally been estimated indirectly
using sentinel surveillance data [1,2] and theoretical
models, with various assumptions [3–5].ippincott Williams & Wilkins. Unauth
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achievements and challenges of the programme have been
described in detail elsewhere [6–10]. In order to facilitate a
rapid scale-up in a healthcare system in which even basic
laboratory services are often not available [11], ART
eligibility is primarily determined by clinical staging [10].
All patients in World Health Organization (WHO) clinical
stages 3 or 4 are generally eligible; if laboratory services are
available, patients in stages 1 or 2 with a CD4 cell count less
than 250 cells/ml (previously< 200 cells/ml) or with a totalorized reproduction of this article is prohibited.
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S106 AIDS 2007, Vol 21 (suppl 6)lymphocyte count of less than 1200 copies/ml are also
eligible for ART. This approach is supported by the WHO
[12]. The estimated numberof individuals needing ART in
Malawi, as of December 2006, was 190 000 and ART
coverage was estimated to be 43% [13].
ARTrollout in Karonga district, northern Malawi, started
in June 2005. As part of data collection procedures for
operational research and as a clinical tool to lead the
clinician systematically through all the AIDS-defining
criteria (thus supplementing their initial clinical assess-
ment), a checklist of symptoms and signs was devised,
with an associated algorithm for determining the
eligibility for ART.
An on-going demographic surveillance system in the
district [14] provided a unique opportunity to estimate
HIV prevalence in the general population, the burden of
HIV disease needing treatment, and to assess the
appropriateness of clinical eligibility criteria for ART
therapy in Malawi. Given the shortage of medical
personnel available in resource-constrained countries
such as Malawi [15], we also tested a simple field-based
staging checklist. This provides the first population-based
data on the distribution of clinical and immunological
stages in Malawi.Methods
The Karonga demographic surveillance system was
established as part of the Karonga Prevention Study, a
large epidemiological study of leprosy and tuberculosis,
which has been running since 1979. Two total population
surveys were conducted in the 1980s. Data from these
surveys and all subsequent studies by the project,
including data on all diagnosed tuberculosis cases in
the district and on Karonga District rollout programme
ART recipients, are held in a linked database.
The demographic surveillance covers a population of
32 000 in an area of 135 km2 in the southern part of the
district. It is divided into 230 ‘clusters’ with an average of
30 households per cluster. After an initial census,
information has been updated using key informants,
reporting at monthly sessions, and visits by field staff
when vital events and changes of household membership
are reported, followed by an update census after 2 years.
Choosing clusters
Stratified sampling of clusters was used to ensure
representative coverage of the whole area. Clusters with
an expected high HIV prevalence were oversampled to
maximize the statistical power in the assessment of the
field checklist. In order to define the ‘high’, ‘medium’
and ‘low’ prevalence strata, project interviewers inde-
pendently scored clusters according to their ownpyright © Lippincott Williams & Wilkins. Unauthorperception of the likely HIV prevalence in that cluster.
Next, the ordered clusters were divided into quintiles of
the total population. The top risk quintile was considered
to be a ‘high-risk’ stratum, the second and third quintiles
a ‘medium-risk’ stratum, and the fourth and fifth
quintiles a ‘low-risk’ stratum. Using probability pro-
portional to size (PPS) sampling, the clusters within each
stratum were assigned cumulated population numbers
and selected at random, and all households within a
cluster were included, to give a total of 750 adults from
each stratum. The sample size changed slightly as
the membership list for some households was updated
at the first visit to reflect recent changes in membership. It
was estimated that 150 HIV-positive individuals in this
sample would contribute to the study comparison of
interest.
All adult members aged between 18 and 59 years within
each selected household were eligible to participate in the
study. Repeated visits were made if necessary. At each
household, the study was introduced and explained to all
members, and then each individual was asked privately for
consent to study participation, physical examination and
HIV testing.
Study procedures
A ‘field checklist’ (Fig. 1) based on a simplified version of
the WHO HIV/AIDS staging criteria was administered
by a health assistant who already had experience
examining for leprosy and skin diseases and drawing
blood for HIV testing. The physical examination was
limited to the face, mouth, lymph nodes, arms and lower
legs. Other areas were only examined if the individual
reported a rash, lesion or skin condition elsewhere. Some
of these visits were conducted by nurses and medical
assistants when available. Staging was later performed by
the use of a computer algorithm.
Participants who, at the time of pretest counselling, had
indicated that they would like to receive their HIV result
were visited for a second time. At this second visit, all
HIV-positive participants were asked for a second blood
sample for CD4 cell count testing and were physically
examined and restaged by a medical assistant using the
‘clinic checklist’ of history, signs and symptoms used in
the ART clinic when ascertaining ARTeligibility (Fig. 2).
Participants identified by the medical assistant to be in
stage III/IV, or stage II with a CD4 cell count less than
250 cells/ml, were given a referral document to facilitate
access to screening by the local ART clinic. Follow-ups
were conducted for those who failed to present at the
ART clinic. A random sample of HIV-negative
participants from each cluster were asked to give a blood
sample for CD4 cell count testing, and to undergo a
second medical review in order to maintain confidenti-
ality of HIV status within the study and to provide an
estimate of the distribution of CD4 cell counts among
HIV-negative individuals in this setting.ized reproduction of this article is prohibited.
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Fig. 1. Field checklist form.Ethics approval for this study was given by the Malawi
National Health Sciences Research Committee (2005,
protocol 354), the London School of Hygiene and
Tropical Medicine, UK (2005, protocol 3054), and
WHO (2005, protocol RPC 130).
HIV testing was conducted with parallel enzyme-linked
immunosorbent assay (Organon, Vironostika, Durham,
North California, USA) and particle agglutination
(Edgware modification of Serodia) tests. Discordant
samples were repeated in duplicate. A second sample
was sought if the original sample remained discordant.
The same algorithm was applied to the second sample, ifopyright © Lippincott Williams & Wilkins. Unauthgiven, and any remaining unresolved samples were
tested using Unigold and Determine rapid tests.
Analyses
All analyses were conducted using Stata version 9.2 (Stata
Corp., College Station, Texas, USA). HIV prevalence
within each cluster was calculated using test results
available from the cluster and assuming that the
prevalence was not significantly different among those
who refused to test. To calculate an overall HIV
prevalence for the demographic surveillance area, the
prevalence estimates for the three strata (low, medium and
high-risk) were weighted to reflect the sampling method.orized reproduction of this article is prohibited.
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Fig. 1. (Continued ).The WHO stage assigned was based on a modified version
of the WHO’s revised clinical staging guidelines [12].
Persistent generalized lymphadenopathy was defined as
lymphadenopathy in two or more sites (excluding
inguinal). For weight loss, the stage II definition was
modified to reported unintentional weight loss but no
obvious thinning, and stage III was defined as reported
unintentionalweight loss and noticeable thinning.Chronic
diarrhea was defined as the report of three or more loose or
watery stools per day for more than one month, con-
tinuously or intermittently. Esophageal candidiasis was
assessed by reported pain or difficulty in swallowing. It was
decided that cryptosporidiosis and isosporiasis would be
indistinguishable from chronic diarrhea in a field setting,
and many of the other stage IV diagnoses, such as pneu-
mocystis pneumonia or toxoplasmosis of the central
nervous system, could not be reliably made in the field, so
these were not included in the checklist. See Figure 1
for details.
Assessment of the utility of the field checklist was only
conducted among participants who had not already started
ART at the time of the study visit. Classification of HIV-pyright © Lippincott Williams & Wilkins. Unauthorpositive participants as eligible for ART (stage III/IV)
versus not eligible (stage I/II) by the field checklist was
compared with classification of the same participant using
the ART clinic checklist. Whether nurses or medical
assistants, i.e. staff with more medical training than health
assistants, administering the field checklist resulted in
higher concordancy with the assigned stage at the second
visit (defined as whether or not each review concluded the
individual was eligible for ART) was also explored.
Discordant classifications were reviewed to identify
limitations in the field checklist. Classification based on
clinical staging alone was compared with classification
based on clinical information and CD4 cell count.
Estimates of the proportion eligible for ART using the
different clinical and immunological criteria were
calculated with and without including participants who
had already started ART.
The project database provided another method of
assessing the usefulness of staging based on reported
illness by establishing the reliability of reports of a history
of tuberculosis and its timing (WHO stage III only ifized reproduction of this article is prohibited.
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Fig. 2. Clinical review form.the pulmonary tuberculosis episode is within the past
2 years).Results
A total of 2129 of 2303 eligible adults (92.4%) were
contacted, of whom 2047 (96.1%) agreed to participate in
the study. Table 1 presents the characteristics of the
population enrolled, overall and by HIV status. Among
the 1443 participants who agreed to testing (70.5%),
11.6% were HIV positive (13.7% of women, 9.1% of
men). Only 24 individuals stated at the first visit that they
did not want to be told their HIV result, two of whom
(8.3%) were HIV positive; 37 others said they were unsure
whether they wanted to know their status and needed
more time to decide.
HIV prevalence in the area, allowing for stratified
sampling, was estimated to be 11.4%, [95% confidence
interval (CI) 11.4, 11.5] overall; 12.8% (95% CI 12.7,
12.9) in the presumed high prevalence strata, 13.3% (95%
CI 13.2, 13.4) in the medium, and 8.9% (95% CI 8.7, 9.0)
in the presumed low prevalence strata. Ten participants
who refused to have their blood tested for HIV in thisopyright © Lippincott Williams & Wilkins. Unauthstudy had been tested by the Karonga Prevention Study
within the past year. Including these test results the
prevalence estimate was virtually unchanged, 11.5%.
Fourteen participants, including nine women (64%),
were identified as already on ART, by self-report at the
study visit or through cross-checking with the project-
linked database. Only one participant refused to be
examined. Table 1 includes the distribution of staging
based on the field checklist at the first visit, among those
who were not already on ART (N¼ 2033). Of the HIV-
positive individuals not on ART, 121 of 158 (76.6%) had
no symptoms and only 14 (8.9%) were classified as eligible
for ART. Sixteen HIV-negative participants (1.3%) were
also classified as stage III/IV. Of these, 12 (75%) had a
report of prolonged fever that contributed to the assigned
stage; for six of these prolonged fever was the only
symptom recorded.
At least one item was missing from the clinical section of
the field checklist for five out of 158 of the HIV-positive
individuals (3.2%). For all five individuals the isolated
missing data could not, however, affect their assigned
stage because they did not have sufficient other symptoms
to reach a WHO stage III or IV definition.orized reproduction of this article is prohibited.
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(% of those tested)
Total 2047 1443 (70.5) 168 (11.6)
SexM
Female 1110 786 (70.8) 108 (13.7)
Male 937 657 (70.1) 60 (9.1)
Women (years)
<20 101 73 (72.3) 8 (11.0)
20–25 259 179 (69.1) 19 (10.6)
25–30 200 131 (65.5) 20 (15.3)
30–35 148 111 (75.0) 20 (18.0)
35–40 111 79 (71.2) 17 (21.5)
40–45 99 71 (71.7) 8 (11.3)
45–50 87 60 (69.0) 9 (15.0)
50þ 105 82 (78 .1) 7 (8.5)
MenMM (years)
<20 102 81 (79.4) 0 (–)
20–25 196 136 (69.4) 5 (3.7)
25–30 176 121 (68.8) 9 (7.4)
30–35 151 102 (67.6) 12 (11.8)
35–40 92 60 (65.2) 15 (25.0)
40–45 73 46 (63.0) 8 (17.4)
45–50 59 42 (71.2) 5 (11.9)
50þ 88 69 (78.4) 6 (8.7)
Education
None 41 28 (68.3) 2 (4.9)
Primary 1274 930 (73.0) 111 (8.7)
Secondary 724 478 (66.0) 54 (7.5)
Tertiary 8 7 (87.5) 1 (12.5)
Current marital statusMM
Married 1451 999 (68.9) 109 (10.9)
Single 342 263 (76.9) 15 (5.7)
Divorced 177 133 (75.1) 24 (18.1)
Widowed 77 48 (62.3) 20 (41.7)
Stage by field checklistMM (N¼2033a)
I Asymptomatic 1938 1355 (69.9) 121 (8.9)
I Symptomatic 8 7 (87.5) 5b (71.4)
II 52 41 (78.9) 18 (43.9)
III 22 18 (81.8) 9 (50.0)
IV 13 12 (92.3) 5 (41.7)
MP<0.01.
MMP<0.001 for comparison between HIV status groups.
aFourteen other individuals were already on antiretroviral therapy.
bAll five individuals had enlarged lymph nodes in more than one area;
one individual also had zoster scars reported but the timing of the
acute episode was not recorded.





Stage I/II Stage III/IV
N (%) N (%)
Stage I/II 116 (87.2) 6 (4.5)b 122 (91.7)
Stage III/IV 5 (3.8)a 6 (4.5) 11 (8.3)
Total 121 (91.0) 12 (9.0) 133 (100)
aAt the first visit, three had reports of prolonged fever for more than
one month within the past 6 months, and two had oral candidiasis
recorded.
bMisclassified antiretroviral therapy eligibility status for four
participants because the field questionnaire did not ask about extra-
pulmonary tuberculosis (one) and serious bacterial infections (three).
One participant reported a history of prolonged fever at the second
visit only, and another reported severe weight loss and pulmonary
tuberculosis within the past 2 years.A second visit was conducted with 1388 of the individuals
who did not refuse to receive their HIV test result and
were not already on ART (98.5%). Of these, 150 were
HIV positive, 133 of whom (88.7%) were restaged.
Twelve HIV-positive participants were referred to the
ART clinic by the medical assistants. No participant started
ART between the twovisits.The median time between the
first and second visit was 20 days (interquartile range 14–29
days). Overall, 93.3% of participants tested in the study
received their HIV test result.
At the first visit, 30 participants (1.5%) reported having
previously been treated for tuberculosis, five of them
within the past 2 years. The project database confirmed
17 (57%, 12 of them pulmonary) and identified three
other participants who had not reported their tubercu-
losis treatment history. At the second visit, one additionalpyright © Lippincott Williams & Wilkins. Unauthorparticipant reported a history of tuberculosis in the last 2
years but this was not confirmed by the project database.
Table 2 provides a comparison of the classification of
treatment eligibility by checklist type. ART eligibility
classification by the field checklist and the clinic checklist
were concordant in 122 of 133 HIV-positive individuals.
Using staging with the clinic checklist as the gold
standard, the field checklist missed six of 12 individuals
who were eligible for ART (i.e. sensitivity 50%), and
incorrectly identified five of 121 individuals as needing
referral for ART (specificity 96%). There was no statis-
tically significant difference in concordance of staging by
the type of health worker administering the
field checklist.
Three of the five misclassifications of individuals as
eligible for ART by field staging were the result of reports
of prolonged fever more than one month within the past
6 months (one of these had also reported a recent history
of chronic diarrhea during field staging). The field
checklist identified oral candidiasis for the other two
individuals, but this was not observed at the second visit.
Four of the six misclassifications of individuals as not
eligible for ART by field staging were caused by the field
checklist not asking about particular conditions: extra-
pulmonary tuberculosis (one individual) and serious
bacterial infections (three individuals).
Of the 133 HIV-positive restaged individuals, 124 (93.2%)
gave blood for CD4 cell count testing although four
specimens failed to give usable results. Table 3 shows a
comparison of the proportions eligible for ART using
clinical and immunological eligibility criteria. All of the
criteria suggest that a higher proportion of HIV-positive
men are eligible for treatment than HIV-positive women.
With the exception of the clinic checklist, however, this
difference was not statistically significant and was generally
explained by the lower average age of HIV-positive women
(Table 1, Table 3). Including those already known to be onized reproduction of this article is prohibited.
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n/N % n/N % n/N % n/N % n/N % n/N %
Sex
Male 6/56 10.7 9/47 19.1 13/46 28.3 17/46 37.0 18/46 39.1 16/46 34.8
Female 8/102 7.8 3/86 3.5 12/74 16.2 18/74 24.3 19/74 25.7 15/74 20.3
P value 0.6 0.004c 0.1 0.1 0.1 0.08
Age (years)
<30 2/61 3.3 3/53 5.7 7/48 14.6 8/48 16.7 10/48 20.8 10/48
30þ 12/97 12.4 9/80 11.3 18/72 25.0 27/72 37.5 27/72 37.5 21/72
P value 0.05 0.3 0.2 0.01d 0.05 0.31
Total excluding
those on ART
14/158 8.9 12/133 9.0 25/120 20.8 35/120 29.2 37/120 30.8 31/120 25.8
Total including
those on ART
28/172 16.3 26/147 17.7 39/134 29.1 49/134 36.6 51/134 38.1 45/134 33.6
ART, Antiretroviral therapy.
aStage III/IV or CD4 cell count less than 250 cells/ml.
bCD4 cell count less than 200 cells/ml or WHO stage IV or (CD4 cell count 200–350 cells/ml and WHO stage III).
cP¼0.01 having adjusted for age using a binary indicator for age less than 30 versus age greater than 30 years.
dP¼0.03 having adjusted for sex.ART, staging by the field checklist and the clinic checklist
estimated ART eligibility as 16.3 and 17.7% of HIV-
positive individuals, respectively, whereas the Malawi
national programme criteria and the 2006 WHO criteria
estimated 38.1 and 33.6%, respectively.
Table 4 compares CD4 cell levels and clinical staging
among HIV-positive individuals not already on ART. For
example, of 35 individuals with CD4 cell counts less than
250 cells/ml, only nine (25.7%) were staged as WHO
stage III/IV. Relying on the CD4 cell count alone
(< 250 cells/ml) missed two out of 11 (18.2%) of those at
WHO stage III/IV. Using the Malawi national pro-
gramme criteria, 30.8% of HIV-positive individuals are
eligible for ART (Table 3, excluding those already on
ART), of whom 11 of 37 (30%) were identified by clinical
staging alone.
Almost half the individuals in stage II had a CD4 cell
count less than 250 cells/ml (20/43; Table 4). Three of
these 20 participants reported moderate unintentionalopyright © Lippincott Williams & Wilkins. Unauth
Table 4. CD4 cell count distribution by WHO stage among HIV-




Stage Ib Stage II Stage III Stage IV
N (%)c N (%) N (%) N (%)
<200 3 (5) 17 (40) 3 (43) 2 (50)
200–350 15 (23) 5 (12) 4 (57) 2 (50)
350 48 (72) 21 (48) 0 (–) 0 (–)
<250 6 (9) 20 (47) 5 (71) 4 (100)
Total (N¼120) 66 43 7 4
aUsing WHO stage classified by the antiretroviral clinic question-
naire.
bIncluding those who were asymptomatic.
cProportion in the WHO stage category meeting the CD4 cell count
criteria.weight loss only, two reported recurrent upper respiratory
tract infections only, four reported herpes zoster within
the past 2 years only, and one had minor mucutaneous
manifestations on examination. Eleven (55%) reported
multiple stage II conditions, which always included
moderate unintentional weight loss.
Eighty-five of the HIV-negative individuals (80.2%)
agreed to a second medical review, but 26 refused to give
a blood sample for CD4 cell count testing. The median
CD4 cell count was 894 cells/ml (interquartile range 704,
1161).Discussion
Acceptance of HIV testing and uptake of HIV test results
were high in this community, and HIV prevalence was
estimated to be 11.4%; 13.7% among women and 9.1%
among men. These estimates and the age-specific patterns
observed are consistent with previous estimates from the
same area [16]. A sampling method that made use of local
perceptions of the likely HIV prevalence in an area was
able to differentiate low prevalence areas, but was less
successful in differentiating between medium and high
prevalence areas.
The field checklist for WHO clinical staging had high
specificity (96%) but low sensitivity (50%) in identifying
individuals eligible for ART, compared with the clinic
checklist. This result is disappointing. This may be an
issue of the small number of individuals who were stage
III/IV. Our investigation of the discordant results
between staging at the first and second visit suggested
that some changes could be made to the field checklist to
improve sensitivity. Adding questions for a history
of extrapulmonary tuberculosis and serious bacterialorized reproduction of this article is prohibited.
Co
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bacterial infections during examination might have
increased the sensitivity of the field checklist, but this
is not easy without the clinical knowledge to probe. Our
study team had previous experience in research studies
and filling in forms. Some had special training in
dermatology and were excellent in diagnosing skin
conditions and lymphadenopathy, whereas others were
nurses with other medical training, but there was no
significant difference in concordance according to the
training of the individual administering the field check-
list. The research experience of our field staff may have
reduced any differences that might have existed from their
formal training, but there is little doubt that they were
more experienced than could be hoped for in other field
settings. This suggests that the field checklist is not an
appropriate screening tool for individual ART eligibility
even though, in this study, it gave a similar estimate of the
proportion needing ART in the community as did the
clinic checklist.
This study suggests that prolonged fever is not useful as an
independent indicator of WHO stage III in an area with
endemic malaria. A similar finding was reported in
Uganda [17]. Our study also suggests that reports of
tuberculosis may not be reliable when collected in a
survey-style approach, although tuberculosis occurring
outside the district would not have been recorded in the
project database. If an ‘improved version’ of our field
checklist were to be used in other settings, linking
tuberculosis self-reports to those collected by the district
tuberculosis programme may be advantageous.
In the absence of direct estimates of ART need, UNAIDS
guidelines (2003) suggested that 15% of all individuals
estimated to have HIV infection should be assumed to
have advanced stage HIV disease [18] when trying
to estimate treatment need. This is approximately equal to
our estimate of overall ART eligibility based on clinical
staging alone if those already on ART are included. We
only included individuals aged 18 years or older, so
slightly higher estimates are expected. A deterministic
model for the whole of Karonga district estimated
that approximately 17.5% of HIV-positive adults (aged
15 years and above) were likely to need ART in 2005 [4].
These estimates are all lower than the estimate obtained
using CD4 cell counts alone or in addition to clinical
criteria. This could partly be caused by bias, if individuals
refusing a second examination and blood test were less
likely to have advanced HIV disease. There is, however,
no evidence that this is the case. Second examinations
were performed for 122 of 144 individuals staged I/II in
the field examination (85%), compared with 11 of 14 of
those staged III/IV (79%), and CD4 cell counts were
available for 109 of 121 of those clinically staged I/II
(90%), compared with 11 of 12 of those staged III/IV
(92%). As an extreme, if all those initially screened butpyright © Lippincott Williams & Wilkins. Unauthorwithout further information are assumed not to be
eligible for ART, the proportion eligible would be 23%
(37/158).
The Malawi national programme criteria provide a higher
estimate of the proportion needing treatment than the
2006 WHO criteria because they suggest that individuals
who are WHO stage III (or stage II and with a CD4 cell
count less than 250 cells/ml) should also receive treatment.
The Malawi criteria are rarely applied in fullwithin Malawi
because of the scarcity of CD4 cell count testing resources.
Malawi’s national programme acknowledges that CD4 cell
counts are helpful in the care of HIV-infected individuals
and has set priorities for CD4 cell testing [11]. Work is
ongoing to find cheaper ways of monitoring CD4 cell
counts [19–21] as well as alternatives to eligibility criteria
that include CD4 cell counts, such as body mass index,
hemoglobin, total lymphocyte count [22] and the
appearance of grey or distal-banded nails [23].
This study demonstrates that focusing upon the clinical
stage alone probably misses two-thirds of those who
would probably benefit from starting treatment. The
importance of CD4 cell counts in staging has been shown
elsewhere, in clinical settings [24–26], but our com-
munity surveillance removes any biases associated with
barriers in accessing care. Limiting ART to those who are
symptomatic may contribute to high early mortality rates.
In settings in which there is not the capacity to start
everyone who becomes eligible, the constraint will
remain the national programme’s capacity to initiate
patients on ART each year.Acknowledgements
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